Mycobacterium Citations List: September 2022

Literature Citations

1. Designing Quinoline-Isoniazid Hybrids as Potent anti-tubercular Agents Inhibiting Mycolic acid Biosynthesis. Alcaraz, M., B. Sharma, F. Roquet-Banères, C. Conde, T. Cochard, F. Biet, V. Kumar, and L. Kremer. European Journal of Medicinal Chemistry, 2022. 239: 114531. PMID[35759907].
[PubMed]. TB_09_2022.

2. In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria. Brown-Elliott, B.A. and R.J. Wallace, Jr. Antimicrobial Agents and Chemotherapy, 2022. 66(9): e0068922. PMID[35943269]. PMCID[PMC9487454].
[PubMed]. TB_09_2022.

3. Intramacrophage Potential of a Tetrahydropyridine: A Promising Compound in Combating Mycobacterium tuberculosis. Halicki, P.C.B., I.L. Pereira, N. Zanatta, V.P. de Andrade, P.E. Almeida da Silva, and D.F. Ramos. Tuberculosis, 2022. 136: 102252. PMID[36063660].
[PubMed]. TB_09_2022.

4. Urea Derivatives Carrying a Thiophenylthiazole Moiety: Design, Synthesis, and Evaluation of Antitubercular and InhA Inhibitory Activities. Keleş Atıcı, R., D. Doğan Ş, M.G. Gündüz, V.S. Krishna, M. Chebaiki, H. Homberset, C. Lherbet, L. Mourey, and T. Tønjum. Drug Development Research, 2022. 83(6): p. 1292-1304. PMID[35769019].
[PubMed]. TB_09_2022.

5. Novel Antibacterial Activity of Febuxostat, an FDA-approved Antigout Drug against Mycobacterium tuberculosis Infection. Kim, L.H., S.M. Kang, J. Whang, K.W. Kwon, and S.J. Shin. Antimicrobial Agents and Chemotherapy, 2022. 66(9): e0076222. PMID[36040172]. PMCID[PMC9487535].
[PubMed]. TB_09_2022.

6. Substituted N-Phenylitaconamides as Inhibitors of Mycobacteria and Mycobacterial Isocitrate Lyase. Krátký, M., E. Novotná, J. Stolaříková, M. Švarcová, and J. Vinšová. European Journal of Pharmaceutical Sciences, 2022. 176: 106252. PMID[35793749].
[PubMed]. TB_09_2022.

7. Discovery and Mechanistic Study of Mycobacterium tuberculosis PafA Inhibitors. Li, C., S. Liu, B.Y. Dong, C.E. Li, L.A. Jian, J. He, J.M. Zeng, Q. Zhou, D. Jia, Y.F. Luo, and Q.X. Sun. Journal of Medicinal Chemistry, 2022: p. 11058-11065. PMID[35926511].
[PubMed]. TB_09_2022.

8. Discovery and Preclinical Evaluations of JBD0131, a Novel Nitrodihydro-Imidazooxazole Anti-tuberculosis Agent. Luo, W., Z. Huang, D. Xu, M. Yang, Y. Zhu, L. Shen, S. Chen, X. Tao, W. Bin, Y. Hu, S.G. Franzblau, N. Jiang, Y. Wei, X. Wei, and C.Z. Ding. Bioorganic & Medicinal Chemistry Letters, 2022. 72: 128871. PMID[35777718].
[PubMed]. TB_09_2022.

9. Activity of Tricyclic Pyrrolopyrimidine gyrase B Inhibitor against Mycobacterium abscessus. Madani, A., D.A. Negatu, A. El Marrouni, R.R. Miller, C.W. Boyce, N. Murgolo, C.J. Bungard, M.D. Zimmerman, V. Dartois, M. Gengenbacher, D.B. Olsen, and T. Dick. Antimicrobial Agents and Chemotherapy, 2022. 66(9): e0066922. PMID[36005813]. PMCID[PMC9487482].
[PubMed]. TB_09_2022.

10. Synthesis of New Thiazole Clubbed Imidazo[2,1-b]thiazole Hybrid as Antimycobacterial Agents. Mahmoud, H.K., A.R. Sayed, M.M. Abdel-Aziz, and S.M. Gomha. Medicinal Chemistry, 2022. 18(10): p. 1100-1108. PMID[35422226].
[PubMed]. TB_09_2022.

11. Synthesis, Characterization and Antitubercular Activities of Heterocyclic Selenosemicarbazones. Malhi, R., J.P. Jasinski, M. Kaur, K. Paul, and R. Sharma. Bioorganic Chemistry, 2022. 126: 105907. PMID[35661528].
[PubMed]. TB_09_2022.

12. Comparative Study of in Vitro Activity of Tedizolid and Linezolid against Mycobacterium avium Complex. Marfil, E., P. Ruiz, L. Martínez-Martínez, and M. Causse. Journal of Global Antimicrobial Resistance, 2022. 30: p. 395-398. PMID[35863729].
[PubMed]. TB_09_2022.

13. Antimicrobial Bioactivity and GC-MS Analysis of Different Extracts of Corchorus olitorius L Leaves. Nakaziba, R., S.B. Amanya, C.D. Sesaazi, F. Byarugaba, J. Ogwal-Okeng, and P.E. Alele. Scientific World Journal, 2022. 2022: 3382302. PMID[36177438]. PMCID[PMC9514938].
[PubMed]. TB_09_2022.

14. Design and Synthesis of Benzimidazole Derivatives as Antimycobacterial Agents. Sindhu, G., R. Kholiya, S. Kidwai, P. Singh, R. Singh, and D.S. Rawat. Journal of Biochemical and Molecular Toxicology, 2022. 36(9): e23123. PMID[35686933].
[PubMed]. TB_09_2022.

15. Synthesis and Structure-Activity Relationships for the Anti-mycobacterial Activity of 3-Phenyl-N-(pyridin-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amines. Sutherland, H.S., P.J. Choi, G.L. Lu, A.C. Giddens, A.S.T. Tong, S.G. Franzblau, C.B. Cooper, B.D. Palmer, and W.A. Denny. Pharmaceuticals, 2022. 15(9). PMID[36145345]. PMCID[PMC9506485].
[PubMed]. TB_09_2022.

16. A Novel Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Expresses anti-Mycobacterium Abscessus Activity in Vitro and in Vivo. Wu, W., S. He, A. Li, Q. Guo, Z. Tan, S. Liu, X. Wang, Z. Zhang, B. Li, and H. Chu. Antimicrobial Agents and Chemotherapy, 2022. 66(9): e0060122. PMID[35969055]. PMCID[PMC9487484].
[PubMed]. TB_09_2022.

Patent Citations

17. Preparation of Indole Derivatives as DNA Primase and Gyrase Inhibitors for Treatment of Microbial Infections. 2022-17750560 20220289677: 53pp.
[Patent]. TB_09_2022.

18. Antibacterial Compounds. Guillemont, J.E.G., M.M.S. Motte, D.A. Lamprecht, and J.M. Bartolome-Nebreda. Patent. 2022. 2022-EP56774 2022194906: 121pp.
[Patent]. TB_09_2022.

19. Antibacterial Compounds. Guillemont, J.E.G., M.M.S. Motte, M.C. Villellas Arilla, G.M.J. Lammens, A.J.D.M. Rene, M.L. Jeanty, and D.A. Lamprecht. Patent. 2022. 2022-EP56588 2022194803: 268pp.
[Patent]. TB_09_2022.

20. Preparation of 3-Substituted phenazine Derivatives as Antimicrobial Agents. Huigens, I.R.W. and H. Yang. Patent. 2022. 2022-17692536 20220289689: 89pp.
[Patent]. TB_09_2022.